pha e agarose  (Vector Laboratories)


Bioz Verified Symbol Vector Laboratories is a verified supplier
Bioz Manufacturer Symbol Vector Laboratories manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 91

    Structured Review

    Vector Laboratories pha e agarose
    Identification of integrin β1 as the target protein bearing bisecting GlcNAc. (a) Intact glycoproteomic analysis by combination <t>of</t> <t>PHA‐E</t> enrichment and LC‐MS/MS (schematic). (b) Venn diagram of numbers of identified glycoproteins bearing bisecting GlcNAc structures in control and MDA‐231/MGAT3. (c) Gene ontology (GO) classification and KEGG pathway analysis of these glycoproteins. (d) Representative MS/MS spectrum of peptide CHEGN # GTFECGACR of β1 with bisecting GlcNAc in MDA/MGAT3 cells. (e) Expression of β1 with bisecting GlcNAc in control and MDA‐231/MGAT3 by immunoprecipitation assay.
    Pha E Agarose, supplied by Vector Laboratories, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pha e agarose/product/Vector Laboratories
    Average 91 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    pha e agarose - by Bioz Stars, 2022-09
    91/100 stars

    Images

    1) Product Images from "Bisecting GlcNAc modification diminishes the pro‐metastatic functions of small extracellular vesicles from breast cancer cells, et al. Bisecting GlcNAc modification diminishes the pro‐metastatic functions of small extracellular vesicles from breast cancer cells"

    Article Title: Bisecting GlcNAc modification diminishes the pro‐metastatic functions of small extracellular vesicles from breast cancer cells, et al. Bisecting GlcNAc modification diminishes the pro‐metastatic functions of small extracellular vesicles from breast cancer cells

    Journal: Journal of Extracellular Vesicles

    doi: 10.1002/jev2.12005

    Identification of integrin β1 as the target protein bearing bisecting GlcNAc. (a) Intact glycoproteomic analysis by combination of PHA‐E enrichment and LC‐MS/MS (schematic). (b) Venn diagram of numbers of identified glycoproteins bearing bisecting GlcNAc structures in control and MDA‐231/MGAT3. (c) Gene ontology (GO) classification and KEGG pathway analysis of these glycoproteins. (d) Representative MS/MS spectrum of peptide CHEGN # GTFECGACR of β1 with bisecting GlcNAc in MDA/MGAT3 cells. (e) Expression of β1 with bisecting GlcNAc in control and MDA‐231/MGAT3 by immunoprecipitation assay.
    Figure Legend Snippet: Identification of integrin β1 as the target protein bearing bisecting GlcNAc. (a) Intact glycoproteomic analysis by combination of PHA‐E enrichment and LC‐MS/MS (schematic). (b) Venn diagram of numbers of identified glycoproteins bearing bisecting GlcNAc structures in control and MDA‐231/MGAT3. (c) Gene ontology (GO) classification and KEGG pathway analysis of these glycoproteins. (d) Representative MS/MS spectrum of peptide CHEGN # GTFECGACR of β1 with bisecting GlcNAc in MDA/MGAT3 cells. (e) Expression of β1 with bisecting GlcNAc in control and MDA‐231/MGAT3 by immunoprecipitation assay.

    Techniques Used: Liquid Chromatography with Mass Spectroscopy, Multiple Displacement Amplification, Tandem Mass Spectroscopy, Expressing, Immunoprecipitation

    Expression of bisecting GlcNAc in breast cancer cells. (a) Relative proportions of N‐glycans in human breast cells were calculated by dividing intensity of given type of N‐glycan by total intensity of sample. (b) Bisecting GlcNAc in normal mammary epithelial cells and BC cells evaluated by PHA‐E lectin staining. (c) Bisecting GlcNAc in serum of BC patient evaluated by ELISA. (d) MALDI‐TOF‐MS analysis of N‐glycans from adjacent normal and matched BC tissue. N‐Glycans were divided into two groups (complex and hybrid; high‐mannose type). Relative proportion of bisecting GlcNAc in complex and hybrid is shown. (e) Bisecting GlcNAc in BC tissues in TMA. Immunohistochemistry of representative paired clinical tissues is shown. (f) MGAT3 expression in normal mammary epithelial cells and BC cells evaluated by immunofluorescence. (g) Representative image of MGAT3 expression and bisecting GlcNAc levels in adjacent normal and matched BC tissues. (h) MGAT3 expression in adjacent normal and matched BC tissues, determined by western blotting and Image Pro Plus software program. (i) mRNA expression of MGAT3 in 112 adjacent normal and matched BC tissues in TCGA database. (j) Differential MGAT3 expression of BC tissues in TMA. (k) Overall survival of dichotomized MGAT3 expression in BC patients in TCGA database using GEPIA platform. (l, m) Overall survival of dichotomized MGAT3 expression (l) and bisecting GlcNAc levels (m) in BC patients by TMA
    Figure Legend Snippet: Expression of bisecting GlcNAc in breast cancer cells. (a) Relative proportions of N‐glycans in human breast cells were calculated by dividing intensity of given type of N‐glycan by total intensity of sample. (b) Bisecting GlcNAc in normal mammary epithelial cells and BC cells evaluated by PHA‐E lectin staining. (c) Bisecting GlcNAc in serum of BC patient evaluated by ELISA. (d) MALDI‐TOF‐MS analysis of N‐glycans from adjacent normal and matched BC tissue. N‐Glycans were divided into two groups (complex and hybrid; high‐mannose type). Relative proportion of bisecting GlcNAc in complex and hybrid is shown. (e) Bisecting GlcNAc in BC tissues in TMA. Immunohistochemistry of representative paired clinical tissues is shown. (f) MGAT3 expression in normal mammary epithelial cells and BC cells evaluated by immunofluorescence. (g) Representative image of MGAT3 expression and bisecting GlcNAc levels in adjacent normal and matched BC tissues. (h) MGAT3 expression in adjacent normal and matched BC tissues, determined by western blotting and Image Pro Plus software program. (i) mRNA expression of MGAT3 in 112 adjacent normal and matched BC tissues in TCGA database. (j) Differential MGAT3 expression of BC tissues in TMA. (k) Overall survival of dichotomized MGAT3 expression in BC patients in TCGA database using GEPIA platform. (l, m) Overall survival of dichotomized MGAT3 expression (l) and bisecting GlcNAc levels (m) in BC patients by TMA

    Techniques Used: Expressing, Staining, Enzyme-linked Immunosorbent Assay, Immunohistochemistry, Immunofluorescence, Western Blot, Software

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 91
    Vector Laboratories pha e agarose
    Identification of integrin β1 as the target protein bearing bisecting GlcNAc. (a) Intact glycoproteomic analysis by combination <t>of</t> <t>PHA‐E</t> enrichment and LC‐MS/MS (schematic). (b) Venn diagram of numbers of identified glycoproteins bearing bisecting GlcNAc structures in control and MDA‐231/MGAT3. (c) Gene ontology (GO) classification and KEGG pathway analysis of these glycoproteins. (d) Representative MS/MS spectrum of peptide CHEGN # GTFECGACR of β1 with bisecting GlcNAc in MDA/MGAT3 cells. (e) Expression of β1 with bisecting GlcNAc in control and MDA‐231/MGAT3 by immunoprecipitation assay.
    Pha E Agarose, supplied by Vector Laboratories, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pha e agarose/product/Vector Laboratories
    Average 91 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    pha e agarose - by Bioz Stars, 2022-09
    91/100 stars
      Buy from Supplier

    Image Search Results


    Identification of integrin β1 as the target protein bearing bisecting GlcNAc. (a) Intact glycoproteomic analysis by combination of PHA‐E enrichment and LC‐MS/MS (schematic). (b) Venn diagram of numbers of identified glycoproteins bearing bisecting GlcNAc structures in control and MDA‐231/MGAT3. (c) Gene ontology (GO) classification and KEGG pathway analysis of these glycoproteins. (d) Representative MS/MS spectrum of peptide CHEGN # GTFECGACR of β1 with bisecting GlcNAc in MDA/MGAT3 cells. (e) Expression of β1 with bisecting GlcNAc in control and MDA‐231/MGAT3 by immunoprecipitation assay.

    Journal: Journal of Extracellular Vesicles

    Article Title: Bisecting GlcNAc modification diminishes the pro‐metastatic functions of small extracellular vesicles from breast cancer cells, et al. Bisecting GlcNAc modification diminishes the pro‐metastatic functions of small extracellular vesicles from breast cancer cells

    doi: 10.1002/jev2.12005

    Figure Lengend Snippet: Identification of integrin β1 as the target protein bearing bisecting GlcNAc. (a) Intact glycoproteomic analysis by combination of PHA‐E enrichment and LC‐MS/MS (schematic). (b) Venn diagram of numbers of identified glycoproteins bearing bisecting GlcNAc structures in control and MDA‐231/MGAT3. (c) Gene ontology (GO) classification and KEGG pathway analysis of these glycoproteins. (d) Representative MS/MS spectrum of peptide CHEGN # GTFECGACR of β1 with bisecting GlcNAc in MDA/MGAT3 cells. (e) Expression of β1 with bisecting GlcNAc in control and MDA‐231/MGAT3 by immunoprecipitation assay.

    Article Snippet: Eluates were lyophilized, dissolved with binding buffer (50 mM NH4 HCO3 , 150 mM NaCl, 1 mM CaCl2 , 1 mM MnCl2, pH 7.4), and incubated with 50 μl PHA‐E‐agarose (Vector Labs) overnight at 4°C.

    Techniques: Liquid Chromatography with Mass Spectroscopy, Multiple Displacement Amplification, Tandem Mass Spectroscopy, Expressing, Immunoprecipitation

    Expression of bisecting GlcNAc in breast cancer cells. (a) Relative proportions of N‐glycans in human breast cells were calculated by dividing intensity of given type of N‐glycan by total intensity of sample. (b) Bisecting GlcNAc in normal mammary epithelial cells and BC cells evaluated by PHA‐E lectin staining. (c) Bisecting GlcNAc in serum of BC patient evaluated by ELISA. (d) MALDI‐TOF‐MS analysis of N‐glycans from adjacent normal and matched BC tissue. N‐Glycans were divided into two groups (complex and hybrid; high‐mannose type). Relative proportion of bisecting GlcNAc in complex and hybrid is shown. (e) Bisecting GlcNAc in BC tissues in TMA. Immunohistochemistry of representative paired clinical tissues is shown. (f) MGAT3 expression in normal mammary epithelial cells and BC cells evaluated by immunofluorescence. (g) Representative image of MGAT3 expression and bisecting GlcNAc levels in adjacent normal and matched BC tissues. (h) MGAT3 expression in adjacent normal and matched BC tissues, determined by western blotting and Image Pro Plus software program. (i) mRNA expression of MGAT3 in 112 adjacent normal and matched BC tissues in TCGA database. (j) Differential MGAT3 expression of BC tissues in TMA. (k) Overall survival of dichotomized MGAT3 expression in BC patients in TCGA database using GEPIA platform. (l, m) Overall survival of dichotomized MGAT3 expression (l) and bisecting GlcNAc levels (m) in BC patients by TMA

    Journal: Journal of Extracellular Vesicles

    Article Title: Bisecting GlcNAc modification diminishes the pro‐metastatic functions of small extracellular vesicles from breast cancer cells, et al. Bisecting GlcNAc modification diminishes the pro‐metastatic functions of small extracellular vesicles from breast cancer cells

    doi: 10.1002/jev2.12005

    Figure Lengend Snippet: Expression of bisecting GlcNAc in breast cancer cells. (a) Relative proportions of N‐glycans in human breast cells were calculated by dividing intensity of given type of N‐glycan by total intensity of sample. (b) Bisecting GlcNAc in normal mammary epithelial cells and BC cells evaluated by PHA‐E lectin staining. (c) Bisecting GlcNAc in serum of BC patient evaluated by ELISA. (d) MALDI‐TOF‐MS analysis of N‐glycans from adjacent normal and matched BC tissue. N‐Glycans were divided into two groups (complex and hybrid; high‐mannose type). Relative proportion of bisecting GlcNAc in complex and hybrid is shown. (e) Bisecting GlcNAc in BC tissues in TMA. Immunohistochemistry of representative paired clinical tissues is shown. (f) MGAT3 expression in normal mammary epithelial cells and BC cells evaluated by immunofluorescence. (g) Representative image of MGAT3 expression and bisecting GlcNAc levels in adjacent normal and matched BC tissues. (h) MGAT3 expression in adjacent normal and matched BC tissues, determined by western blotting and Image Pro Plus software program. (i) mRNA expression of MGAT3 in 112 adjacent normal and matched BC tissues in TCGA database. (j) Differential MGAT3 expression of BC tissues in TMA. (k) Overall survival of dichotomized MGAT3 expression in BC patients in TCGA database using GEPIA platform. (l, m) Overall survival of dichotomized MGAT3 expression (l) and bisecting GlcNAc levels (m) in BC patients by TMA

    Article Snippet: Eluates were lyophilized, dissolved with binding buffer (50 mM NH4 HCO3 , 150 mM NaCl, 1 mM CaCl2 , 1 mM MnCl2, pH 7.4), and incubated with 50 μl PHA‐E‐agarose (Vector Labs) overnight at 4°C.

    Techniques: Expressing, Staining, Enzyme-linked Immunosorbent Assay, Immunohistochemistry, Immunofluorescence, Western Blot, Software